

Prof. BURCU ÇALIŞKAN

Personal Information

Office Phone: [+90 312 202 3212](tel:+903122023212)

Email: bcaliskan@gazi.edu.tr

Web: <https://avesis.gazi.edu.tr/bcaliskan>

International Researcher IDs

ScholarID: M9rWU8YAAAAJ

ORCID: 0000-0003-2391-5644

Publons / Web Of Science ResearcherID: AAF-9101-2021

ScopusID: 56724752200

Yoksis Researcher ID: 124323

Education Information

Doctorate, Gazi University, Sağlık Bilimleri Enstitüsü, Farmasotik Kimya (Dr), Turkey 2004 - 2008

Postgraduate, Gazi University, Sağlık Bilimleri Enstitüsü, Farmasotik Kimya (YI) (Tezli), Turkey 2001 - 2004

Undergraduate, Ankara University, Eczacılık Fakültesi, Eczacılık Pr., Turkey 1997 - 2001

Dissertations

Doctorate, 1,5-diarilpirazol-3-propanoik asit yapısı taşıyan COX/5-LOX dual inhibitörü bileşiklerin sentezi ve in vitro inhibitör etki tayinleri üzerinde çalışmalar, Gazi University, Sağlık Bilimleri Enstitüsü, Farmasotik Kimya (Dr), 2008

Postgraduate, Yeni tipte tiyopirano[2,3-b]piridin türevlerinin sentezi üzerinde araştırmalar, Gazi University, Sağlık Bilimleri Enstitüsü, Farmasotik Kimya (YI) (Tezli), 2004

Research Areas

Health Sciences, Pharmacology and Therapeutics, Pharmaceutical Chemistry

Academic Titles / Tasks

Professor, Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri, 2019 - Continues

Associate Professor, Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri, 2013 - 2019

Research Assistant, Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri, 2002 - 2013

Academic and Administrative Experience

Academic Performance D. Board Member, Gazi University, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri, 2021 - Continues

Advising Theses

Çalışkan B., Benzotiyazol türevi mikrozomal prostaglandin E2 sentaz-1 (mPGES-1) inhibitörlerinin geliştirilmesi, Doctorate, T.YALÇIN(Student), 2023

Çalışkan B., Yeni benzimidazol türevlerinin sentezi ve mikrozomal prostaglandin E2 Sentaz-1 (mPGES-1) inhibitörü etkilerinin incelenmesi, Doctorate, A.GİZEM(Student), 2022

Çalışkan B., BAZI VİSİNAL DİARİL HETEROSİKLİK BİLEŞİKLERİN ANTİKANSER AKTİVİTELERİNİN ARAŞTIRILMASI, Doctorate, S.TURANLI(Student), 2021

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Novel 1,3,4-oxadiazole derivatives as highly potent microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors**
Gür Maz T., Dahlke P., Gizem Ergül A., OLĞAÇ A., Jordan P. M., ÇALIŞKAN B., Werz O., BANOĞLU E.
Bioorganic Chemistry, vol.147, 2024 (SCI-Expanded)
- II. **Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer**
Gedik M. E., Saatci O., Oberholtzer N., ÜNER M., Akbulut Caliskan O., Cetin M., Aras M., ÇALIŞKAN K., ÇALIŞKAN B., BANOĞLU E., et al.
Cancer research, vol.84, no.9, pp.1475-1490, 2024 (SCI-Expanded)
- III. **Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification**
Saatci O., Akbulut O., Cetin M., Sikirzhytski V., ÜNER M., LENGERLİ D., O'Quinn E. C., Romeo M. J., ÇALIŞKAN B., BANOĞLU E., et al.
Cell Death and Differentiation, vol.30, no.5, pp.1305-1319, 2023 (SCI-Expanded)
- IV. **Design, Synthesis and Evaluation of Aryl-Tailored Oxadiazole-thiones as New Urease Inhibitors**
Gür Maz Z. T., Caliskan H. B., Capan İ., Caliskan B., Özçelik B., Banoglu E.
CHEMISTRYSELECT, vol.8, no.8, 2023 (SCI-Expanded)
- V. **Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors.**
Gür Maz Z. T., Koç B., Jordan P. M., İbiş K., Çalışkan B., Werz O., Banoğlu E.
ACS OMEGA, vol.8, no.2, pp.2445-2454, 2023 (SCI-Expanded)
- VI. **Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with in Vitro Growth Inhibitory and in Vivo Antitumor Activity**
Turanlı S., NALBAT E., LENGERLİ D., İBİŞ K., Güntekin Ergün S., Akhan Güzelcan E., MUYAN M., Cetin-Atalay R., Çalışkan B., BANOĞLU E.
ACS Omega, vol.7, no.41, pp.36206-36226, 2022 (SCI-Expanded)
- VII. **Quinazoline-4(3H)-one-7-carboxamide Derivatives as Human Soluble Epoxide Hydrolase Inhibitors with Developable 5-Lipoxygenase Activating Protein Inhibition**
TURANLI S., Ergul A. G., Jordan P. M., OLĞAÇ A., ÇALIŞKAN B., Werz O., BANOĞLU E.
ACS OMEGA, vol.7, no.41, pp.36354-36365, 2022 (SCI-Expanded)
- VIII. **Development and molecular modeling studies of new thiadiazole piperazine urea derivatives as potential fatty acid amide hydrolase inhibitors**
Gür Maz Z. T., Turanlı S., Çalışkan H. B., Çalışkan B., Banoğlu E.
ARCHIV DER PHARMAZIE, vol.355, no.8, pp.1-11, 2022 (SCI-Expanded)
- IX. **Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors.**
Çapan İ., Jordan P. M., Olğaç A., Çalışkan B., Kretzer C., Werz O., Banoglu E.
ChemMedChem, vol.17, no.12, 2022 (SCI-Expanded)
- X. **Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase**
Ergül A. G., Maz T. G., Kretzer C., Olğaç A., Jordan P. M., Çalışkan B., Werz O., Banoğlu E.
European Journal of Medicinal Chemistry, vol.231, 2022 (SCI-Expanded)

- XI. **Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells**
Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.221, 2021 (SCI-Expanded)
- XII. **Simple heteroaryl modifications in the 4,5-diarylisoaxazol-3-carboxylic acid scaffold favorably modulates the activity as dual mPGES-1/5-LO inhibitors with in vivo efficacy**
Gurses T., OLĞAÇ A., Garscha U., GÜR MAZ Z. T., BAL N. B., Uludag O., ÇALIŞKAN B., Schubert U. S., Werz O., BANOĞLU E.
BIOORGANIC CHEMISTRY, vol.112, 2021 (SCI-Expanded)
- XIII. **Exploration of anti-tyrosinase effect of Geranium glaberrimum Boiss. & Heldr. with in silico approach and survey of 21 Geranium species**
Celikler Ozer O., Erdoğan Orhan İ., Çalışkan B., Senol Deniz F. S., Gokbulut A., Gur Maz T., Aysal A. İ., Emerce E., Shekfeh S., Kahraman A., et al.
JOURNAL OF HERBAL MEDICINE, vol.27, 2021 (SCI-Expanded)
- XIV. **Antimigratory effect of pyrazole derivatives through the induction of STAT1 phosphorylation in A549 cancer cells**
Şimay Demir Y. D., Özdemir A., Özdemir R. G., Cevher S. C., Çalışkan B., Ark M.
JOURNAL OF PHARMACY AND PHARMACOLOGY, vol.73, no.6, pp.808-815, 2021 (SCI-Expanded)
- XV. **A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate**
Akbulut O., Lengerli D., Saatci O., Duman E., ŞEKER U. Ö. Ş., Isik A., AKYOL A., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.
MOLECULAR CANCER THERAPEUTICS, vol.19, no.6, pp.1243-1254, 2020 (SCI-Expanded)
- XVI. **Evaluation of Cytotoxic Activity of New Benzimidazole-Piperazine Hybrids Against Human MCF-7 and A549 Cancer Cells**
ÖZDEMİR A., Thranli S., ÇALIŞKAN B., Arka M., BANOĞLU E.
Pharmaceutical Chemistry Journal, vol.53, no.11, pp.1036-1046, 2020 (SCI-Expanded)
- XVII. **Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors**
Uslu A. G., Maz T. G., Nocentini A., BANOĞLU E., Supuran C. T., ÇALIŞKAN B.
BIOORGANIC CHEMISTRY, vol.95, 2020 (SCI-Expanded)
- XVIII. **Novel Piperazine Amides of Cinnamic Acid Derivatives as Tyrosinase Inhibitors**
GÜR MAZ Z. T., ŞENOL DENİZ F. S., Shekfeh S., ERDOĞAN ORHAN İ., BANOĞLU E., ÇALIŞKAN B.
LETTERS IN DRUG DESIGN & DISCOVERY, vol.16, no.1, pp.36-44, 2019 (SCI-Expanded)
- XIX. **A Multi-step Virtual Screening Protocol for the Identification of Novel Non-acidic Microsomal Prostaglandin E-2 Synthase-1 (mPGES-1) Inhibitors**
Shekfeh S., ÇALIŞKAN B., Fischer K., Yalcin T., Garscha U., Werz O., BANOĞLU E.
CHEMMEDCHEM, vol.14, no.2, pp.273-281, 2019 (SCI-Expanded)
- XX. **Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents**
ÇALIŞKAN B., NALBAT E., Ibis K., Guzelcan E. A., ATALAY R., BANOĞLU E.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol.33, no.1, pp.1352-1361, 2018 (SCI-Expanded)
- XXI. **Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis**
Gür Maz Z. T., Çalışkan B., Banoğlu E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.153, pp.34-48, 2018 (SCI-Expanded)
- XXII. **Identification of multi-target inhibitors of leukotriene and prostaglandin E-2 biosynthesis by structural tuning of the FLAP inhibitor BRP-7**
GÜR MAZ Z. T., ÇALIŞKAN B., Garscha U., OLĞAÇ A., Schubert U. S., Gerstmeier J., Werz O., BANOĞLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.150, pp.876-899, 2018 (SCI-Expanded)
- XXIII. **BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly**

- Garscha U, Voelker S, Pace S, Gerstmeier J, Emini B, Liening S, Rossi A, Weinigel C, Rummler S, Schubert U. S., et al.
BIOCHEMICAL PHARMACOLOGY, vol.119, pp.17-26, 2016 (SCI-Expanded)
- XXIV. **Synthesis and biological evaluation of C(5)-substituted derivatives of leukotriene biosynthesis inhibitor BRP-7**
Levent S, Gerstmeier J, Olğaç A, Nikels F, Garscha U, Carotti A, Macchiarulo A, Werz O, Banoğlu E, Çalışkan B.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.122, pp.510-519, 2016 (SCI-Expanded)
- XXV. **4,5-Diarylisoaxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)**
Banoğlu E, Celikoglu E, Voelker S, Olğaç A, Gerstmeier J, Garscha U, Çalışkan B, Schubert U. S., Carotti A, Macchiarulo A, et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.113, pp.1-10, 2016 (SCI-Expanded)
- XXVI. **Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines**
Piról S. C., ÇALIŞKAN B., Durmaz I., ATALAY R., BANOĞLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.87, pp.140-149, 2014 (SCI-Expanded)
- XXVII. **The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP)**
Pergola C., Gerstmeier J, Moench B, Caliskan B, Luderer S., Weinigel C., Barz D., Maczewsky J, Pace S, Rossi A, et al.
British Journal of Pharmacology, vol.171, no.12, pp.3051-3064, 2014 (SCI-Expanded)
- XXVIII. **Chromatographic separation and biological evaluation of benzimidazole derivative enantiomers as inhibitors of leukotriene biosynthesis**
Sardella R., Levent S, Ianni F., ÇALIŞKAN B., Gerstmeier J, Pergola C., Werz O, BANOĞLU E., Natalini B.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol.89, pp.88-92, 2014 (SCI-Expanded)
- XXIX. **Pyrazole derivatives as inhibitors of arachidonic acid-induced platelet aggregation**
Levent S., ÇALIŞKAN B., Ciftci M., ÖZKAN Y., Yenicesu I., ÜNVER H., BANOĞLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.64, pp.42-53, 2013 (SCI-Expanded)
- XXX. **Synthesis and evaluation of analgesic, anti-inflammatory, and anticancer activities of new pyrazole-3(5)-carboxylic acid derivatives**
ÇALIŞKAN B., Yilmaz A., Evren I., Menevse S., Uludag O., BANOĞLU E.
MEDICINAL CHEMISTRY RESEARCH, vol.22, no.2, pp.782-793, 2013 (SCI-Expanded)
- XXXI. **Overview of recent drug discovery approaches for new generation leukotriene A(4) hydrolase inhibitors**
ÇALIŞKAN B., BANOĞLU E.
EXPERT OPINION ON DRUG DISCOVERY, vol.8, no.1, pp.49-63, 2013 (SCI-Expanded)
- XXXII. **Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP)**
BANOĞLU E., ÇALIŞKAN B., Luderer S., EREN G., Ozkan Y., Altenhofen W., Weinigel C., Barz D., Gerstmeier J., Pergola C., et al.
BIOORGANIC & MEDICINAL CHEMISTRY, vol.20, no.12, pp.3728-3741, 2012 (SCI-Expanded)
- XXXIII. **Pyrazol-3-propanoic acid derivatives as novel inhibitors of leukotriene biosynthesis in human neutrophils**
ÇALIŞKAN B., Luderer S., Ozkan Y., Werz O., BANOĞLU E.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.46, no.10, pp.5021-5033, 2011 (SCI-Expanded)
- XXXIV. **Synthesis, antioxidant and antimicrobial evaluation of simple aromatic esters of ferulic acid**
Ergun B., ÇOBAN T., Onurdag F. K., BANOĞLU E.
Archives of Pharmacol Research, vol.34, no.8, pp.1251-1261, 2011 (SCI-Expanded)
- XXXV. **Stable ester and amide conjugates of some NSAIDs as analgesic and antiinflammatory compounds with improved biological activity**
ULUDAĞ M. O., Ergun B., Alkan D. A., Ercan N., Ozkan G. Y., BANOĞLU E.

- Turkish Journal of Chemistry, vol.35, no.3, pp.427-439, 2011 (SCI-Expanded)
- XXXVI. **Synthesis of 1,5-diarylpyrazol-3-propanoic acids towards inhibition of cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB₄ formation**
Ergun B., Teresa Nunez M., Labeaga L., Ledo F., Darlington J., Bain G., Cakir B., BANOĞLU E.
Arzneimittel-Forschung/Drug Research, vol.60, no.8, pp.497-505, 2010 (SCI-Expanded)
- XXXVII. **Synthesis and chromatographic resolution of conformationally constrained analogues of homotaurine**
Fulco M. C., Marinozzi M., Ergun B., Sardella R., Natalini B., Pellicciari R.
TETRAHEDRON, vol.65, no.42, pp.8756-8762, 2009 (SCI-Expanded)
- XXXVIII. **Screening and evaluation of antioxidant activity of some pyridazine derivatives**
Caliskan-Erguen B., Suekueroglu M. K., ÇOBAN T., BANOĞLU E., SÜZEN S.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol.23, no.2, pp.225-229, 2008 (SCI-Expanded)
- XXXIX. **Synthesis of the amide derivatives of 3-[1-(3-pyridazinyl)-5-phenyl-1H-pyrazole-3-yl]propanoic acids as potential analgesic compounds**
BANOĞLU E., Sukuroglu M. K., Ergun B., BAYTAŞ S., Aypar E., Aark M.
TURKISH JOURNAL OF CHEMISTRY, vol.31, no.6, pp.677-687, 2007 (SCI-Expanded)
- XL. **Screening and evaluation of rat kidney aldose reductase inhibitory activity of some pyridazine derivatives**
Sukuroglu M. K., Caliskan-Ergun B., Das-Evcimen N., Sarikaya M., Banoğlu E., Suzen S.
MEDICINAL CHEMISTRY RESEARCH, vol.15, pp.443-451, 2007 (SCI-Expanded)
- XLI. **Synthesis, analgesic, and anti-inflammatory activities of [6-(3,5-dimethyl-4-chloropyrazole-1-yl)-3(2H-pyridazinon-2-yl)]acetamides**
Sukuroglu M. K., Ergun B., Unlu S., Sahin M., Kupeli E., Yesilada E., BANOĞLU E.
ARCHIVES OF PHARMACAL RESEARCH, vol.28, no.5, pp.509-517, 2005 (SCI-Expanded)
- XLII. **Synthesis of amide derivatives of [6-(3,5-dimethylpyrazol-1-yl)-3(2H)-pyridazinone-2-yl]acetic acid and their analgesic and anti-inflammatory properties**
BANOĞLU E., Akoglu C., Unlu S., Ergun B., Kupeli E., Yesilada E., Sahin M.
Arzneimittel-Forschung/Drug Research, vol.55, no.9, pp.520-527, 2005 (SCI-Expanded)

Articles Published in Other Journals

- I. **Synthesis and evaluation of antibacterial and antimycobacterial activities of some new pyrazole derivatives**
Gür Maz Z. T., Karaca N., Levent S., Çalışkan B., Demirci F., Banoğlu E.
JOURNAL OF RESEARCH IN PHARMACY, vol.25, no.5, pp.531-539, 2021 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **A Tale of Two 5-Lipoxygenase Activating Protein (FLAP) Inhibitors**
OLĞAÇ A., TURANLI S., ÇAPAN İ., Dahlke P., ERGÜL A. G., Jordan P. M., ÇALIŞKAN B., Werz O., BANOĞLU E.
Gordon Research Seminar on Computer Aided Drug Design, Vermont, United States Of America, 15 - 16 July 2023
- II. **A Tale of Two Diverse Sets of Novel 5-Lipoxygenase Activating Protein (FLAP) Inhibitors**
OLĞAÇ A., TURANLI S., ÇAPAN İ., Dahlke P., ERGÜL A. G., Jordan P. M., ÇALIŞKAN B., Werz O., BANOĞLU E.
International Multidisciplinary Symposium on Drug Research and Development (DRD) 2023, İzmir, Turkey, 04 May 2023
- III. **DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL IMIDAZOLIDINONE-THIAZOLE AMIDE HYBRIDS AS INHIBITORS OF HUMAN SOLUBLE EPOXIDE HYDROLASE**
İbiş K., Lengerli D., Jordan P. M., Çalışkan B., Werz O., Banoğlu E.
9th EFMC Young Medicinal Chemists' Symposium, Nice, France, 8 - 09 September 2022

- IV. **Novel Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors as a New Modality To Treat Inflammation**
ÇALIŞKAN B., ERGÜL A. G., GÜR MAZ Z. T., KRETZER C., OLĞAÇ A., JORDAN P. M., WERZ O., BANOĞLU E.
XXVII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMIC 2022), Nice, France, 4 - 08 September 2022
- V. **NOVEL BENZOTHAZOLE DERIVATIVES AS MICROSOMAL PROSTAGLANDINE E2 SYNTHASE-1 (mPGES-1) INHIBITORS**
YALÇIN T., GÜR MAZ Z. T., KRETZER C., ÇALIŞKAN B., WERZ O., BANOĞLU E.
9th EFMC Young Medicinal Chemists' Symposium (EFMC-YMCS 2022), Nice, France, 8 - 09 September 2022
- VI. **STUDIES ON THE SYNTHESIS AND ANTICANCER POTENTIAL OF NOVEL 2,4-DIAMINOPYRIMIDINE DERIVATIVES**
Lengerli D., Akbulut Çalışkan Ö., Çalışkan B., Şahin Ö., Banoğlu E.
The 9th Young Medicinal Chemist Symposium (EFMC-YMCS 2022), Nice, France, 8 - 09 September 2022
- VII. **Evaluation of Oxadiazole Derivatives as Promising Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors**
GÜR MAZ Z. T., ERGÜL A. G., JORDAN P. M., ÇALIŞKAN B., WERZ O., BANOĞLU E.
XXVII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMIC 2022), Nice, France, 4 - 08 September 2022
- VIII. **TACC3 İnhibitörü Yeni 2,4-Diaminopirimidin Türevlerinin Sentezi, Anti-Kanser Etki Potansiyelleri ve İlaç Benzeri Özelliklerinin Değerlendirilmesi Üzerine Çalışmalar**
LENGERLİ D., AKBULUT ÇALIŞKAN Ö., ÇALIŞKAN B., ŞAHİN Ö., BANOĞLU E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Turkey, 26 August 2022
- IX. **KARACIĞER KANSERİ KÖK HÜCRELERİ ÜZERİNDE İNHİBİTÖR ETKİYE SAHİP, POTANSİYEL ANTİKANSER AJANLAR OLARAK YENİ İZOKSAZOL-PIPERAZİN HİBRİTLERİNİN SENTEZİ VE BİYOLOJİK OLARAK DEĞERLENDİRİLMESİ**
İbiş K., Nalbat E., Çalışkan B., Atalay R., Banoğlu E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Turkey, 26 - 29 August 2022
- X. **Bazı Visinal Diaril Heterosiklik Bileşiklerin Antikanser Aktivitelerinin Araştırılması**
Turanlı S., Nalbat E., Akhan Güzelcan E., Atalay R., Çalışkan B., Banoğlu E.
VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Turkey, 26 - 29 August 2022, pp.42-44
- XI. **SELECTIVE OR DUAL INHIBITORS OF INFLAMMATORY PGE2 AND LTB4 BIOSYNTHESIS BY TARGETING mPGES-1 AND FLAP TO INTERVENE WITH INFLAMMATORY DEREGULATION**
BANOĞLU E., ÇALIŞKAN B., ERGÜL A. G., GÜR MAZ Z. T., OLĞAÇ A., WERZ O.
The Sixth International Symposium on Pharmaceutical and Biomedical Sciences (ISPBS-6), Gaziantep, Turkey, 26 - 28 May 2022
- XII. **Discovery of Novel Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors: A New Modality to Treat Inflammation**
Banoğlu E., Çalışkan B., Ergül A. G., Gür Maz Z. T., Kretzer C., Olğaç A., Jordan P. M., Werz O.
10th International Drug Chemistry Conference, Antalya, Turkey, 10 - 13 March 2022
- XIII. **Novel isoxazole- piperazine derivatives inhibit the stemness of HCC cells**
NALBAT E., İBİŞ K., ÇALIŞKAN B., BANOĞLU E., ATALAY M. V., ATALAY R.
AASLD-TASL Digital Hepatology Meeting, Ankara, Turkey, 15 January 2022, pp.5-6
- XIV. **NOVEL PIPERAZINYL UREA DERIVATIVES AS POTENTIAL FATTY ACID AMIDE HYDROLASE (FAAH) INHIBITORS**
TURANLI S., ÇALIŞKAN H. B., GÜR MAZ Z. T., ÇALIŞKAN B., BANOĞLU E.
3rd International Gazi Pharma Symposium Series, 08 September 2021
- XV. **Synthesis of 3,4-Diaryl-5-methylisoxazoles with Potent Antiproliferative Activity Against a Panel of Human Liver and Breast Cancer Cell Lines**
LENGERLİ D., TURANLI S., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., BANOĞLU E.
EFMC-ISMIC EFMC-YMCS Virtual Poster Session, 09 September 2020
- XVI. **Vicinal Diaryl Heterocyclic Compounds with Potential Anticancer Activity**

- TURANLI S., ÇALIŞKAN B., AKHAN GÜZELCAN E., GÜNTEKİN ERGÜN S., ATALAY R., BANOĞLU E.
EFMC-ISMV EFMC-YMCS Virtual Poster Session, 09 September 2020
- XVII. **Synthesis of New Vicinal Diaryl Five-Membered Heterocyclic Compounds with Potential Anticancer Activity**
TURANLI S., LENGERLİ D., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., BANOĞLU E.
8th International Drug Chemistry Conference, 27 February - 01 March 2020
- XVIII. **Discovery of Multitarget Inhibitors in the Arachidonic Acid Pathway by Targeting FLAP/5-LO/mPGES-1 for Intervention with Inflammatory Deregulation**
BANOĞLU E., ÇALIŞKAN B., GÜR MAZ Z. T., OLĞAÇ A., Garscha U., Werz O.
8th International Drug Chemistry Conference, Antalya, Turkey, 27 February - 01 March 2020
- XIX. **A SMALL MOLECULE INHIBITOR OF TRANSFORMING ACIDIC COILED-COIL PROTEIN 3 (TACC3): A NOVEL THERAPEUTIC STRATEGY FOR THE TREATMENT OF BREAST CANCER**
LENGERLİ D., Akbulut O., ÇALIŞKAN B., ŞAHİN Ö., BANOĞLU E.
11th Joint Meeting on Medicinal Chemistry 2019, PRAG, Czech Republic, 27 - 30 June 2019
- XX. **Abstract 3871: A novel TACC3 inhibitor as an anti-cancer agent in breast cancer**
Akbulut O., LENGERLİ D., Saatci O., Duman E., Seker U., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.
Experimental and Molecular Therapeutics, 29 March - 03 April 2019
- XXI. **A Novel TACC3 inhibitor as an anti-cancer agent in breast cancer**
AKBULUT ÇALIŞKAN Ö., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., ŞAHİN Ö.
30th EORTC-NCI-AACR Symposium, Dublin, Ireland, 13 - 16 November 2018
- XXII. **Antimigratory Effect of a Newly Synthesized Pyrazole Derivative Compound in A549 Cancer Cells**
ÖZDEMİR A., Gönbe Özdemir R., ŞİMAY DEMİR Y. D., Cevher S. C., Şahinoğlu E., ÇALIŞKAN B., ARK M.
DGZ International Meeting, 17 - 19 September 2018, vol.44
- XXIII. **Antimigratory Effect of a Newly Synthesized Pyrazole Derivative Compound in A549 Cancer Cells**
ÖZDEMİR A., özdemir r., Şimay y., cevher s., şahinoğlu e., ÇALIŞKAN B., ARK M.
DGZ International Meeting, 17 - 19 September 2018
- XXIV. **EVOLUTION OF SELECTIVE FLAP INHIBITOR BRP-7 INTO MULTI-TARGET INHIBITOR OF FLAP, 5-LO AND MPGES-1 IN THE ARACHIDONIC ACID PATHWAY**
GÜR MAZ Z. T., ÇALIŞKAN B., OLĞAÇ A., GERSTMEIER J., GARSCHA U., WERZ O., BANOĞLU E.
EFMC International Symposium on Medicinal Chemistry, Ljubljana, Slovenia, 2 - 06 September 2018, pp.231
- XXV. **SYNTHESIS, CYTOTOXICITY AND STRUCTURE-ACTIVITY RELATIONSHIPS OF NOVEL ISOXAZOLE DERIVATIVES AS ANTICANCER AGENTS**
İbiş K., ÇALIŞKAN B., AKHAN GÜZELCAN E., Sinoplu E., ATALAY R., BANOĞLU E.
RICT 2018, 4 - 06 July 2018
- XXVI. **SYNTHESIS AND ANTIPROLIFERATIVE EVALUATION OF NOVEL ISOXAZOLE-PIPERAZINE HYBRIDS**
ÇALIŞKAN B., Sinoplu E., İbiş K., AKHAN GÜZELCAN E., ATALAY R., BANOĞLU E.
RICT 2018, 4 - 06 July 2018
- XXVII. **ANTİLÖKOTRİEN ETKİLİ 1,2,5-TRİSÜBSTİTÜEBENZİMİDAZOL TÜREVLERİNİN GELİŞTİRİLMESİ ÜZERİNDE YAPILAN ÇALIŞMALAR**
GÜR MAZ Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., WERZ O., BANOĞLU E.
V. ULUSAL FARMASÖTİK KİMYA KONGRESİ, Erzurum, Turkey, 28 April - 01 May 2018
- XXVIII. **Discovery of Tyrosinase Inhibitors from Geranium glaberrimum Boiss. Heldr. Using In Vitro and In Silico Methods**
Çelikler Ö., ŞENOL DENİZ F. S., ÇALIŞKAN B., GÜR MAZ Z. T., KAHRAMAN A., ERDOĞAN ORHAN İ., BANOĞLU E.
The 4th Mediterranean Symposium on Medicinal and Aromatic Plants (MESMAP-2018), 18 - 22 April 2018
- XXIX. **Discovery and Development of Novel Anti-cancer and Anti-inflammatory Compounds: Medicinal Chemistry Challenges**
BANOĞLU E., ÇALIŞKAN B., GÜR MAZ Z. T., OLĞAÇ A., İBİŞ K., Akhan Güzelcam E., Sinoplu E., Garscha U., Gerstmeier J., ATALAY R., et al.
The 4th International Symposium on Pharmaceutical and Biomedical Sciences, Kumamoto, Japan, 17 March 2018
- XXX. **Developing Multi-target Inhibitors of Arachidonic Acid Pathway Based on the FLAP Inhibitor BRP-7**

GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., WERZ O., BANOĞLU E.

2nd International Gazi Pharma Symposium Series, 11 - 13 October 2017

- XXXI. **FROM BATCH TO CONTINUOUS FLOW CHEMISTRY:DOE-ASSISTED OPTIMIZATION OF BENZIMIDAZOL-2-ONESYNTHESIS**
GÜR Z. T., MOSTARDA S., PICCINNO A., ÇALIŞKAN B., BANOĞLU E., GIOIELLO A.
2nd International Gazi Pharma Symposium Series, 11 - 13 October 2017
- XXXII. **Discovery of Dual FLAP/mPGES-1 Inhibitors for Intervention with Inflammatory Diseases:Medicinal Chemistry Challenges**
BANOĞLU E., ÇALIŞKAN B., GÜR Z. T., OLĞAÇ A.
Turkish Japanese Workshop on Bioorganic Medicinal Chemistry Natural Products, 14 September 2017
- XXXIII. **Tirozinaz İnhibitör Etkili Yeni Sinnamik Asit Türevleri**
ÇALIŞKAN B., GÜR Z. T., ŞENOL F. S., SHEKFEH S., ERDOĞAN ORHAN İ., BANOĞLU E.
29. Ulusal Kimya Kongresi, Turkey, 10 - 14 September 2017, pp.452
- XXXIV. **Discovery of Novel Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors Using Structure-Based Virtual Screening.**
Shekfeh S., Katrin F., ÇALIŞKAN B., Garscha U., Werz O., BANOĞLU E.
EFMC-ASMC 2017 International Symposium on Advances in Synthetic and Medicinal Chemistry, 27 - 31 August 2017
- XXXV. **Bioisosteric Tuning of FLAP Inhibitor BRP-7 Towards a More Potent Antiinflammatory Agent with Multiligand Inhibitor Properties in the Arachidonic Acid (AA) Pathway**
GÜR Z. T., ÇALIŞKAN B., OLĞAÇ A., GERSTMEIER J., GARSCHA U., WERZ O., BANOĞLU E.
EFMC-ASMC'xx17 EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry, 27 - 31 August 2017
- XXXVI. **Araşidonik asit yolağında çoklu ligand (FLAP/5-LO/mPGES-1) özellikte inhibitör etkili BRP-7 türevlerinin geliştirilmesi**
BANOĞLU E., GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., OLĞAÇ A., GARSCHA U., WERZ O.
1. Anadolu Üniversitesi Eczacılık Sempozyumu, Eskişehir, Turkey, 1 - 02 June 2017, pp.10
- XXXVII. **İzoksazol Türevi Bileşiklerin in-vivo Analjezik ve Antienflamatuvar Aktivitesi Üzerinde Çalışmalar Örnek Ö.** HAN S., ÇALIŞKAN B., BANOĞLU E., ULUDAĞ M. O.
3rd International Convention of Pharmaceuticals and Pharmacies, İstanbul, Turkey, 26 - 29 April 2017, pp.738
- XXXVIII. **Diarilpirazol Türevi Bileşiğın (BRP-42) Analjezik ve Antienflamatuvar Aktivitesi Üzerinde Çalışmalar** GÖKER G., HAN S., ÇALIŞKAN B., BANOĞLU E., ULUDAĞ M. O.
3rd International Convention of Pharmaceuticals and Pharmacies, İstanbul, Turkey, 26 - 29 April 2017, pp.752
- XXXIX. **5-Sübstitüe-Benzimidazol Türevi Bileşiğın Farelerde Analjezik ve Antienflamatuvar Aktivite Tarama Çalışması**
Göker S., HAN S., ÇALIŞKAN B., BANOĞLU E., ULUDAĞ M. O.
3rd International Convention of Pharmaceuticals and Pharmacies, İstanbul, Turkey, 26 - 29 April 2017, pp.732
- XL. **Anticancer activity of novel benzimidazole derivatives against MCF-7 cancer cells**
ÖZDEMİR A., UZUNOĞLU S., ÇALIŞKAN B., BANOĞLU E., ARK M.
Experimental Biology 2017, Chicago, 22 - 26 April 2017, vol.31
- XLI. **Anticancer activity of novel benzimidazole derivatives against MCF-7 cancer cells**
ÖZDEMİR A., Uzunoglu S., ÇALIŞKAN B., BANOĞLU E., ARK M.
Experimental Biology Meeting, Illinois, United States Of America, 22 - 26 April 2017, vol.31
- XLII. **Novel BRP 7 Derivatives Targeting FLAP Potent Inhibitors of Leukotriene Biosynthesis**
GÜR Z. T., ÇALIŞKAN B., GERSTMEIER J., GARSCHA U., OLĞAÇ A., WERZ O., BANOĞLU E.
3rd EFMC Young Medicinal Chemist Symposium, Manchester, United Kingdom, 1 - 02 September 2016
- XLIII. **EXPLORATION OF THE CHEMICAL SPACE AROUND C 5 POSITION OF THE BENZIMIDAZOLE NUCLEUS IN BRP 7 TOWARDS MORE POTENT INHIBITORS OF HUMAN 5 LIPOXYGENASE ACTIVATING PROTEIN FLAP**
GÜR Z. T., ÇALIŞKAN B., Gerstmeier J., OLĞAÇ A., nikels F., werz o., BANOĞLU E.
EFMC International Symposium on Medicinal Chemistry, Manchester, United Kingdom, 28 August - 01 September

2016

- XLIV. **Discovery of 4 5 Diarylisoxazol 3 Carboxylic Acid Skeleton as a Novel Chemotype for Inhibition of 5 Lipoxygenase Activating Protein FLAP**
ÇALIŞKAN B., ÇELİKOĞLU E., GERSTMEIER J., VOELKER S., GARSCHA U., OLĞAÇ A., CAROTTI A., MACCHIARULO A., WERZ O., BANOĞLU E.
EFMC International Symposium on Medicinal Chemistry 2016, Manchester, United Kingdom, 28 August - 01 September 2016
- XLV. **DISCOVERY OF 4 5 DIARYLISOXAZOL 3 CARBOXYLIC ACID SKELETON AS A NOVEL CHEMOTYPE FOR INHIBITION OF 5 LIPOXYGENASE ACTIVATING PROTEIN FLAP**
ÇALIŞKAN B., çelikoğlu e., gerstmeier j., voelker s., garscha u., OLĞAÇ A., carotti a., Macchiarulo A., werz o., BANOĞLU E.
EFMC International Symposium on Medicinal Chemistry, Manchester, United Kingdom, 28 August - 01 September 2016
- XLVI. **STRUCTURE BASED DESIGN AND SYNTHESIS OF NOVEL BRP 7 DERIVATIVES BEARING C 5 POLAR SUSBTITUENTS AS POTENT FLAP INHIBITORS**
GÜR Z. T., OLĞAÇ A., Gerstmeiner J., Macchiarulo A., Werz O., ÇALIŞKAN B., BANOĞLU E.
GPSS 2015, Antalya, Turkey, 12 - 15 November 2015
- XLVII. **Structure-Based Design and Synthesis of Novel BRP-7 Derivatives as Potent FLAP Inhibitors: Insights from MolecularDynamics Simulations.**
OLĞAÇ A., GÜR Z. T., CAROTTI A., ÇALIŞKAN B., GERSTMEIER J., WERZ O., MACCHIARULO A., BANOĞLU E.
EFMC International Symposium on Medicinal Chemistry, LÍZBON, Portugal, 7 - 11 September 2014, pp.162
- XLVIII. **New 4,5-Diarylisoazole Derivatives as Novel Inhibitors of Human 5-Lipoxygenase (5-LO)**
ÇALIŞKAN B., LUDERER S., GERSTMEIER J., EREN G., WERZ O., BANOĞLU E.
EFMC-ISMC 2012, XXIIInd International Symposium on Medicinal Chemistry, Berlin, Germany, 2 - 06 September 2012
- XLIX. **New Isoxazole Derivatives as Novel Inhibitors of 5-Lipoxygenase**
ÇALIŞKAN B., LUDERER S., EREN G., WERZ O., BANOĞLU E.
4th International Symposium on Advanced in Synthetic and Medicinal Chemistry, St. Petersburg, Russia, 21 - 25 August 2011
- L. **Homology Modeling of Human 5-Lipoxygenase and Molecular Docking Simulations of Competitive Inhibitors**
EREN G., ÇALIŞKAN B., COSTANTINO G., MACCHIARULO A., ÜNLÜ S., ÇAKIR B., BANOĞLU E., PELLICCIARI R.
3rd International Meeting on Medicinal and Pharmaceutical Chemistry, IMMPC-3, Antalya, Turkey, 16 - 21 October 2007

Supported Projects

GÜR MAZ Z. T., BANOĞLU E., KOÇ B., ÇALIŞKAN B., İBİŞ K., WERZ O., JORDAN P. M., Project Supported by Higher Education Institutions, Bazı Yeni İndol Türevi Çözünür Epoksit Hidrolaz İnhibitörlerinin Geliştirilmesi Üzerine Çalışmalar, 2024 - Continues

ÇALIŞKAN K., KARATAŞ M., JORDAN P. M., BANOĞLU E., ÇALIŞKAN B., WERZ O., Project Supported by Higher Education Institutions, Dual FLAP/sEH İnhibitörlerinin Geliştirilmesi Üzerine Çalışmalar, 2023 - Continues

Banoğlu E., Gür Maz Z. T., Uludağ M. O., Çalışkan B., Olğaç A., Bal N. B., TUBITAK Project, Yeni Mikrozomal Prostaglandin E2 Sentaz-1 (Mpges-1) İnhibitörlerinin Geliştirilmesi Üzerine Çalışmalar, 2019 - 2023

GÜR MAZ Z. T., BANOĞLU E., ÇALIŞKAN B., TURANLI S., Project Supported by Higher Education Institutions, Yeni Piperazinilüre Türevlerinin sentezi ve FAAH İnhibitörü Aktivitelerinin İncelenmesi, 2020 - 2022

Gür Maz Z. T., Çalışkan B., Banoğlu E., Demirci F., Project Supported by Higher Education Institutions, Pirazol-5-karboksilik asit sülfonamid türevlerinin sentezi ve antimikrobiyal aktivitelerinin değerlendirilmesi, 2017 - 2019

Banoğlu E., Çalışkan B., Atalay R., Muyan M., TUBITAK Project, Meme ve Karaciğer Kanserinin Tedavisi İçin PI3K Akt Sinyal Yolunu Hedefleyen Yeni İlaç Aday Molekül Geliştirme ve Ön Klinik Çalışmaları, 2016 - 2019

Banođlu E., alıřkan B., TUBITAK Project, Meme ve Karaciđer Kanserinin Tedavisi iin PI3K/Akt Sinyal Yolunu Hedefleyen Yeni Aday İla Moleköl Geliřtirme ve Ön klinik alıřmaları, 2016 - 2019

Banođlu E., alıřkan B., Atalay R., TUBITAK Project, Antikanser Etkili Olabilecek Yeni İzoksazol Türevlerinin Sentezi Yapı Etki İliřkileri Ve Moleküler Etki Mekanizmalarının İncelenmesi Üzerinde Arařtırmalar, 2015 - 2018

Banođlu E., alıřkan B., TUBITAK Project, 5 Lipoksijenaz aktive edici protein FLAP inhibitörlerinin geliřtirilmesi, 2013 - 2016

ALIřKAN B., Project Supported by Higher Education Institutions, N-Arilsülfonil benzimidazol-2-karboksamid türevlerinin sentezi, 2011 - 2013

ALIřKAN B., Project Supported by Higher Education Institutions, Pirazol-5-karboksilik asit amit ve ester türevlerinin sentezi, 2010 - 2012

Banođlu E., alıřkan B., TUBITAK Project, 5-Lipoksijenaz 5-LOX ve FLAP inhibitörleri Enflamatuvar ve kardiyovasküler hastalıklarda etkili olabilecek yeni bileřiklerin moleküler modelleme yöntemleriyle tasarımı sentezi ve aktivitelerinin incelenmesi, 2008 - 2011

Patent

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin Ö., Lim C., Cruz E., Vempati S., EP22788722 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP/22788722.1 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin Ö., Lim C., Cruz E., Vempati S., AU2022256380 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022256380 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin Ö., Lim C., Cruz E., Vempati S., CA3216541 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 3216541 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin Ö., Akbulut B., Lim C., Cruz E., Vempati S., HK62023072323.6 ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 62023072323.6 , Standard Registration, 2023

Banođlu E., alıřkan B., řahin Ö., Lim C., Vempati S., US18/389078 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 18/389078 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., řahin Ö., Akbulut Ö., JP7301958 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE, Patent, CHAPTER A Human Needs, The Invention Registration Number: 7301958 , Standard Registration, 2023

Banođlu E., alıřkan B., řahin Ö., Lengerli D., Akbulut Ö., US11622966 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE, Patent, CHAPTER A Human Needs, The Invention Registration Number: US11622966 , Standard Registration, 2023

Banođlu E., alıřkan B., Muyan M., Atalay R., Erson Bensan A. E., Lengerli D., Güntekin S., Turanlı S., İbiř K., ANTİKANSER AKTİVİTEYE SAHİP YENİ VİSİNAL DİARİL HETEROSİKLİK BİLEřİK TÜREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: TR 2019 14610 B , Standard Registration, 2023

Banođlu E., alıřkan B., řahin Ö., Lim C., Vempati S., PCT/US23/16132 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/US23/16132 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin Ö., Lim C., Cruz E., Vempati S., CN202280041301.1 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 202280041301.1 , Standard Registration, 2023

Banođlu E., alıřkan B., Lengerli D., alıřkan K., řahin Ö., Lim C., Cruz E., Vempati S., NZ805433 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 805433 , Standard Registration, 2023

Banođlu E., alıřkan B., řahin Ö., Lim C., Vempati S., TW112110936 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 112110936 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., JP562485 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2023-562485 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., KR10-2023-7038832 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 10-2023-7038832 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., EP3801529B1 HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE, Patent, CHAPTER A Human Needs, The Invention Registration Number: EP3801529B1 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., US18/286469 COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: 18/286469 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., Çalışkan K., Şahin Ö., Lim C., Cruz E., Vempati S., IN202327073452 COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 202327073452 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Ergül A. G., Gür Maz Z. T., Werz O., Jordan P. M., BENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF, Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/TR2023/050887 , Standard Registration, 2023

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Lim C., Cruz E., Vempati S., TW111113780-COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 111113780 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Gür Maz Z. T., Ergül A. G., Werz O., Jordan P. M., BENZIMIDAZOLE DERIVATIVE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 (MPGES-1) INHIBITORS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/TR2022/050178 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Vempati S., Lim C., Cruz E., KR10-2022-7020047-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: KR10-2022-7020047 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Şahin Ö., Vempati S., Lim C., US63/323,339-COMPOSITIONS AND METHODS FOR TREATING CANCER , Patent, CHAPTER A Human Needs, The Invention Recourse Number: US63/323,339 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Vempati S., Lim C., Cruz E., CN 202080091759.9 (2022110200431050)-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: CN 115279754 A (2022072000921700) , Standard Registration, 2022

Banoğlu E., Çalışkan B., İbiş K., Lengerli D., Şahin Ö., Akbulut Ö., Lim C., Cruz E., Vempati S., JP2022-527677-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022-527677 , Standard Registration, 2022

Banoğlu E., Çalışkan B., İbiş K., Lengerli D., Şahin Ö., Akbulut Ö., Lim C., Cruz E., Vempati S., EP20888312.4-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: EP/20888312.4 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Vempati S., Lim C., Cruz E., PCT/US2022/024263 (WO2022/221194 A1) COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US22/24263 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., İbiş K., Şahin Ö., Akbulut Ö., Lim C., Vempati S., Cruz E., US17/776,767-ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US17/776,767 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Gür Maz Z. T., Ergül A. G., Werz O., Jordan P. M., BENZİMİDAZOL TÜREVİ MİKROZOMAL PROSTAGLANDİN E2 SENTAZ-1 (mPGES-1) İNHİBİTÖRLERİ, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 2022/011123 , Standard Registration, 2022

Banoğlu E., Çalışkan B., Lengerli D., Şahin Ö., Akbulut Ö., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-HongKong, Patent, CHAPTER A Human Needs, The Invention Recourse Number: 62021037626.0 , 2021

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Lim C., Cruz E., Vempati S., COMPOSITIONS AND METHODS FOR TREATING CANCER, Patent, CHAPTER A Human Needs, The Invention Recourse Number: US63173796 , 2021

Banođlu E., alıřkan B., Lengerli D., řahin ., Akbulut ., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-CN, Patent, CHAPTER A Human Needs, The Invention Recourse Number: CN201980049280.6 , 2021

Banođlu E., alıřkan B., Atalay R., Akhan Gzelcan E., İbiř K., ANTİKANSER AKTİVİTEYE SAHİP YENİ İZOKSAZOL TREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: 2017 19951 , Standard Registration, 2021

Banođlu E., alıřkan B., Lengerli D., İbiř K., řahin ., Akbulut ., Lim C., Vempati S., Cruz E., ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS (US/PCT), Patent, CHAPTER A Human Needs, The Invention Recourse Number: PCT/US/2020/060588 , 2020

Banođlu E., alıřkan B., řahin ., Lengerli D., Akbulut ., ANTİ-KANSER AJANI OLARAK KULLANILABİLECEK YENİ POTANSİYEL TACC3 İNHİBİTR (BRP-OZG-264), Patent, CHAPTER A Human Needs, The Invention Registration Number: 2018 07464 , Standard Registration, 2020

Banođlu E., alıřkan B., Lengerli D., řahin ., Akbulut ., HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE-KR, Patent, CHAPTER A Human Needs, The Invention Recourse Number: KR10-2020-7037075 , 2020

Banođlu E., Eren G., alıřkan B., elikođlu E., Levent S., Werz O., Voelker S., Garscha U., Altenhofen W., LKOTRİEN BİYOSENTEZ İNHİBİTRLERİ OLARAK İZOKSAZOL TREVLERİ, Patent, CHAPTER A Human Needs, The Invention Registration Number: 2014 05943 , Standard Registration, 2016

Metrics

Publication: 95

Citation (WoS): 666

Citation (Scopus): 841

H-Index (WoS): 17

H-Index (Scopus): 18